Abstract
Respiratory tract infections (RTIs) are the most frequent infections in humans, particularly in children. In addition to intervention, increasing interest is focusing on immunomodulatory therapy for recurrent RTIs, which indicate a reduced defense capacity of the respiratory mucosa. LW 50020, an oral immunomodulator that contains the antigens of seven bacteria common in RTIs, has reduced the number, duration, and severity of RTIs in children and adults. This 56-week placebocontrolled, double-blind study in 188 children investigated whether the efficacy of the standard schedule (immunization cycle + one booster cycle) would be enhanced by additional booster cycles. Efficacy and safety over the long term were also assessed. The rate of infection was reduced by 50% with the standard schedule and could not be further decreased by two consecutive booster cycles. With both schedules, this reduction was sustained during a 28-week treatmentfree observation period that followed the 28-week treatment period. The number of adverse drug reactions was low, and all were transient, expected, and nonserious. These results confirm that LW 50020 is an effective and safe strategy for RTIs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bellanti JA. Recurrent respiratory tract infections in pediatric patients.Drugs. 1997;54:1–4.
Towns S, Wong M. Assessment of the child with recurrent respiratory infections.Aust Fam Physician. 2000;29:741–746.
Wassermann RL, Sorensen RU. Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine.Pediatr Infect Dis J. 1999;18:157–163.
Korppi M. Recurrent respiratory infections in children: a practical approach for clinical work.Pediatr Pulmonol. 1997;16:144–145.
Nafstad P, Hagen JA, Oie L, Magnus P, Jaakkola JJK. Day care centers and respiratory health.Pediatrics. 1999;103:753–758.
Ferrari M, Tardivo S, Zanolin ME, et al. Serious childhood respiratory infections and asthma in adult life. A population based study.Ann Allergy Asthma Immunol. 1999;83:391–396.
Paoletti P, Prediletto R, Carrozzi L, et al. Effects of childhood and adolescence-adulthood respiratory infections in a general population.Eur Respir J. 1989;2:428–436.
Celedon JC, Litonjua AA, Weiss ST, Gold DR. Day care attendance in the first year of life and illnesses of the upper and lower respiratory tract in children with a familial history of atopy.Pediatrics. 1999;104:495–500.
Jedrychowski W, Maugeri U, Flak E, Mroz E, Bianchi I. Predisposition to acute respiratory infections among overweight preadolescent children: an epidemiologic study in Poland.Public Health. 1998;112:189–195.
Van Cauwenberge PB, Belussi L, Maw AR, Paradise JL, Solow B. The adenoid as a key factor in upper airway infections.Int J Pediatr Otorhinolaryngol. 1995;32(suppl.):71–80.
Lundbäck B. Epidemiology of rhinitis and asthma.Clin Exp Allergy. 1998;28:3–10.
Bolte G, Mielck A, Meyer I, Stiller-Winkler R, Heinrich J. Inverse social gradient of secondary immune response parameters in children.Rev Environ Health. 1999;14:135–143.
Shapiro ED. Epidemiology of acute respiratory infections.Semin Pediatr Infect Dis. 1998;9:31–36.
Latal Hajnal B, Braun-Fahrländer C, Grize L, et al. Effect of environmental tobacco smoke exposure on respiratory symptoms in children.Schweiz Med Wochenschr. 1999;129:723–730.
Jedrychowski W, Flak E. Maternal smoking during pregnancy and postnatal exposure to environmental tobacco smoke as predisposition factors to acute respiratory infections.Environ Health Perspect. 1997;105:302–306.
Drummond PD, Hewson-Bower B. Increased psychological stress and decreased mucosal immunity in children with recurrent upper respiratory tract infections.J Psychosom Res. 1997; 43:271–278.
Helmberg A, Böck G, Wolf H, Wick G. An orally administered bacterial immunomodulator primes rabbit neutrophils for increased oxidative burst in response to opsonized zymosan infection.Immunology. 1989;57:3576–3580.
Ruedl CH, Albin B, Böck G, Wick G, Wolf H. Oral administration of a bacterial immunomodulator enhances murine intestinal lamina propria and Peyer’s patch lymphocyte traffic to the lung: possible implications for infectious disease prophylaxis and therapy.Int Immunol. 1993;5:29–36.
Ruedl CH, Frühwirt M, Wick G, Wolf H. Immune response in the lungs following oral immunization with bacterial lysates of respiratory pathogens.Clin Diagn Lab Immunol. 1994;1:150–154.
Van Daal GJ, Beusenberg FD, So KL, et al. Protection against influenza virus infection in mice by oral immunization with a polyvalent bacterial lysate.Int J Immunol. 1991;13:831–840.
Van Daal GJ, van’t Veen A, So KL, et al. Oral immunization with polyvalent bacterial lysate and infection withStreptococcus pneumoniae: influence on interferon-gamma and PMN-elastase concentrations in murine bronchoalveolar lavage fluid.Int Immunol. 1993;5:29–36.
Wichels R, Wolfschaffner F, Guggenbichler JP. Prophylaxis of infections.TW Pädiatrie. 1996;9: 421–423.
Riedl-Seifert RJ, van Aubel A, Kämmereit A, et al. Recurrent infections during childhood: are they still a “crux medicorum”? [in German].J Pharmacol Ther. 1992;2:108–117.
Rutishauser M, Pitzke P, van Aubel A, Elsasser U, Grevers G, Kämmereit A. Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections.Adv Ther. 1998;15:330–341.
Gooch WM. Potential infectious disease complications of upper respiratory tract infections.Pediatr Infect Dis J. 1998;17:79–82.
Openshaw PJ, Lemanske RF. Respiratory viruses and asthma: can the effects be prevented?Eur Respir J. 1998;12(suppl 27):35S-39S.
Mushatt DM. Advances in antimicrobial therapy for respiratory tract infections.Curr Opin Pulm Med. 2000;6:250–253.
Staats HF, McGhee JR. Application of basic principles of mucosal immunity to vaccine development. In: Kiyono H, Ogra PL, McGhee JR, eds.Mucosal Vaccines. San Diego, Calif: Academic Press; 1996: 17–39.
Stead RH, Bienenstock J. Development of new oral vaccines and immunomodulators. In: Riedl-Seifert RJ, ed.Mucosal Immunology. Munich: Zuckschwerdt Verlag; 1998:119–128.
Walker RI. New strategies for using mucosal vaccination to achieve more effective immunization.Vaccine. 1994;12:387–400.
Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved.Epidemiol Infect. 1993;110:145–160.
Jones NS. Current concepts in the management of pediatric rhinosinusitis.J Laryngol Otol. 1999; 113:1–9.
Stögmann W. Das infektanfällige Kind.Tägl Pract. 1992;3:283–294.
Grevers G, Aldrey O, Rodriguez B, Abel S, van Aubel A. Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: results of an open, prospective, multinational study.Adv Ther. 2000;7:103–116.
Büchner KR.Treatment of Out-Patients With Recurrent Respiratory Tract Infections. Bayreuth, Germany: PCO Publisher; 1994.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ruah, S.B., Ruah, C., van Aubel, A. et al. Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv Therapy 18, 151–162 (2001). https://doi.org/10.1007/BF02850109
Issue Date:
DOI: https://doi.org/10.1007/BF02850109